CV Therapeutics, Inc.’s (NASDAQ: CVTX)

CV Therapeutics, Inc.’s (NASDAQ: CVTX) primary focused is on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. The company is devoted to discovering new solutions for the unmet medical needs of patients. By emphasizing on discovery science and small molecule therapeutics, the company’s drug candidates are usually able to be produced by conventional pharmaceutical manufacturing methods. For further information, visit the Company’s web site at www.cvt.com.